Cytokinetics (CYTK) Free Cash Flow (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Free Cash Flow of -$151.4 million for Q1 2026, down 10.31% year-over-year from -$168.8 million in Q1 2025, and up 8.42% quarter-over-quarter from -$165.4 million in Q4 2025.
Cytokinetics (CYTK) Free Cash Flow (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Free Cash Flow for 17 consecutive years, with -$151.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 10.31% year-over-year to -$151.4 million; the TTM figure through Mar 2026 stood at -$549.0 million (down 34.88% YoY), while the FY2025 annual figure was -$534.8 million, down 33.96% from the prior year.
- Free Cash Flow improved to -$151.4 million in Q1 2026 per CYTK's latest filing, from -$165.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$27.8 million in Q1 2022 and bottomed at -$165.4 million in Q4 2025.
- Historically, Free Cash Flow has averaged -$106.5 million across 5 years, with a median of -$101.9 million in 2024.
- On a YoY basis, Free Cash Flow climbed as much as 28.3% in 2023 and fell as far as 342.33% in 2023.
- Cytokinetics' Free Cash Flow stood at -$101.4 million in 2022, then climbed by 28.3% to -$72.7 million in 2023, then climbed by 5.84% to -$68.5 million in 2024, then plunged by 141.57% to -$165.4 million in 2025, then advanced by 8.42% to -$151.4 million in 2026.
- Business Quant data shows CYTK's Free Cash Flow at -$151.4 million in Q1 2026, -$165.4 million in Q4 2025, and -$106.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | -164.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -164.13 Mn |
| Jun 30, 2026 | -164.13 Mn |
| Mar 31, 2026 | -151.43 Mn |
| Mar 31, 2026 | -151.43 Mn |
| Dec 31, 2025 | -165.36 Mn |
| Dec 31, 2025 | -165.36 Mn |
| Sep 30, 2025 | -106.76 Mn |
| Sep 30, 2025 | -106.76 Mn |
| Jun 30, 2025 | -125.40 Mn |
| Jun 30, 2025 | -125.40 Mn |
| Mar 31, 2025 | -137.28 Mn |
| Mar 31, 2025 | -137.28 Mn |
| Dec 31, 2024 | -68.45 Mn |
| Dec 31, 2024 | -68.45 Mn |
| Sep 30, 2024 | -101.89 Mn |
| Sep 30, 2024 | -101.89 Mn |
| Jun 30, 2024 | -99.38 Mn |
| Jun 30, 2024 | -99.38 Mn |
| Mar 31, 2024 | -129.51 Mn |
| Mar 31, 2024 | -129.51 Mn |